September was a significant month for the companies that support the life sciences industry like CROs, CDMOs, and suppliers, as well as digital health companies.
Welcome to the August edition of Changing Faces’ digital and supplier edition. This was a bit of a slower month, but it wasn’t completely without notable moves.
The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.